These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 9757491)

  • 1. [ 40 years of 5-fluorouracil--still an attractive cytostatic].
    Hofer S; Herrmann R
    Schweiz Med Wochenschr; 1998 Aug; 128(34):1253-60. PubMed ID: 9757491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Importance of 5-fluorouracil dose-intensity in a double randomised trial on adjuvant portal and systemic chemotherapy for Dukes B2 and C colorectal cancer.
    Focan C; Bury J; Beauduin M; Herman ML; Vindevoghel A; Lecomte M; Brohée D; Canon JL; Focan-Henrard D;
    Anticancer Res; 2000; 20(6C):4665-72. PubMed ID: 11205198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Timeline from discovery of 5-FU to development of an oral anticancer agent S-1 and its drug concept].
    Shirasaka T; Taguchi T
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():4-18. PubMed ID: 16897967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of 5-fluorouracil host-toxicity and chemotherapeutic efficacy against human colon tumors by 5-(Phenylthio)acyclouridine, a uridine phosphorylase inhibitor.
    Al Safarjalani ON; Rais R; Shi J; Schinazi RF; Naguib FN; el Kouni MH
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):692-8. PubMed ID: 16528530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Possible regulation of 5-fluorouracil-induced neuro- and oral toxicities by two biochemical modulators consisting of S-1, a new oral formulation of 5-fluorouracil.
    Kato T; Shimamoto Y; Uchida J; Ohshimo H; Abe M; Shirasaka T; Fukushima M
    Anticancer Res; 2001; 21(3B):1705-12. PubMed ID: 11497250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer.
    Chau I; Webb A; Cunningham D; Hill M; Waters JS; Norman A; Massey A
    Br J Cancer; 2001 Nov; 85(9):1258-64. PubMed ID: 11720458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer.
    Di Paolo A; Danesi R; Vannozzi F; Falcone A; Mini E; Cionini L; Ibrahim T; Amadori D; Del Tacca M
    Clin Pharmacol Ther; 2002 Dec; 72(6):627-37. PubMed ID: 12496744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity.
    Cianci G; Morelli MF; Cannita K; Morese R; Ricevuto E; Di Rocco ZC; Porzio G; Lanfiuti Baldi P; Ficorella C
    Br J Cancer; 2003 May; 88(10):1507-9. PubMed ID: 12771913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologic behavior of microsatellite-unstable colorectal cancer and treatment with 5-fluorouracil.
    Niv Y
    Isr Med Assoc J; 2005 Aug; 7(8):520-4. PubMed ID: 16106779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy.
    Yoshikawa R; Kusunoki M; Yanagi H; Noda M; Furuyama JI; Yamamura T; Hashimoto-Tamaoki T
    Cancer Res; 2001 Feb; 61(3):1029-37. PubMed ID: 11221829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis.
    Thirion P; Michiels S; Pignon JP; Buyse M; Braud AC; Carlson RW; O'Connell M; Sargent P; Piedbois P;
    J Clin Oncol; 2004 Sep; 22(18):3766-75. PubMed ID: 15365073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advanced colorectal cancer: quality of life and toxicity in patients after weekly 24-hour continuous infusions of biomodulated 5-fluorouracil.
    Bogliolo G; Pannacciulli I; Desalvo L; Barsotti B; Lerza R; Mencoboni M; Arboscello E
    Anticancer Res; 2000; 20(1B):501-4. PubMed ID: 10769713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
    Emura T; Suzuki N; Yamaguchi M; Ohshimo H; Fukushima M
    Int J Oncol; 2004 Sep; 25(3):571-8. PubMed ID: 15289858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of action of fluoropyrimidines: relevance to the new developments in colorectal cancer chemotherapy.
    Sobrero A; Guglielmi A; Grossi F; Puglisi F; Aschele C
    Semin Oncol; 2000 Oct; 27(5 Suppl 10):72-7. PubMed ID: 11049035
    [No Abstract]   [Full Text] [Related]  

  • 15. A randomized phase II trial of 5-fluorouracil, with or without human interferon-beta, for advanced colorectal cancer.
    Villar-Grimalt A; Candel MT; Massuti B; Lizón J; Sánchez B; Frau A; Gorostidi B; Goedkoop R
    Br J Cancer; 1999 May; 80(5-6):786-91. PubMed ID: 10360656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I and pharmacokinetic study of tomudex combined with 5-fluorouracil plus levofolinic acid in advanced head and neck cancer and colorectal cancer.
    Caponigro F; Avallone A; McLeod H; Cartenì G; De Vita F; Casaretti R; Morsman J; Blackie R; Budillon A; De Lucia L; Gravina A; Catalano G; Comella P; Comella G
    Clin Cancer Res; 1999 Dec; 5(12):3948-55. PubMed ID: 10632324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The dihydrouracil/uracil ratios in plasma and toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients.
    Zhou ZW; Wang GQ; Wan de S; Lu ZH; Chen YB; Li S; Chen G; Pan ZZ
    Chemotherapy; 2007; 53(2):127-31. PubMed ID: 17308379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of action of topical 5-fluorouracil: review and implications for the treatment of dermatological disorders.
    Ceilley RI
    J Dermatolog Treat; 2012 Apr; 23(2):83-9. PubMed ID: 21034289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case of 5-fluorouracil-induced peripheral neuropathy.
    Werbrouck BF; Pauwels WJ; De Bleecker JL
    Clin Toxicol (Phila); 2008 Mar; 46(3):264-6. PubMed ID: 18344111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selectivity in human breast cancer and human bone marrow using trimetrexate in combination with 5-fluorouracil.
    Bowen D; Johnson DH; Southerland WM; Hughes DE; Hawkins M
    Anticancer Res; 1999; 19(5B):3837-40. PubMed ID: 10628320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.